tesamorelin
Tesamorelin vs CJC-1295 Listing Differences
A side-by-side look at how tesamorelin vs CJC-1295 listing differences show up in naming, vial sizing, documentation, and price-per-mg presentation across sellers.
Medically reviewed by Catherine Dumont, MD, physician and clinical researcher — Last reviewed
Catherine Dumont, MD is a physician with clinical and research training in endocrinology and growth hormone therapeutics, with post-graduate research in GHRH analog applications and growth hormone axis disorders.
Tesamorelin and CJC-1295 are both GHRH analogs, but that shared category masks real differences in how listings describe them. The two compounds diverge in vial sizing conventions, naming precision, and how much structural detail a seller includes, and reading tesamorelin vs CJC-1295 listing differences correctly means looking past the shared “GHRH analog” label to the specifics each listing actually states.
Same Category, Different Molecules
Tesamorelin is a modified 44-amino-acid GHRH analog with a defined, stable structure. CJC-1295 is a shorter GHRH fragment analog that exists in two distinct listed forms: with a Drug Affinity Complex (DAC) attached, or without one. Listings that just say “CJC-1295” without specifying DAC status are leaving out a structurally meaningful detail, since the DAC and non-DAC versions are chemically different molecules with different listed half-lives. Tesamorelin listings don’t carry this same naming ambiguity, since there’s only one tesamorelin structure in circulation. A careful comparison of tesamorelin vs CJC-1295 listing differences has to start here, because the CJC-1295 side of the comparison isn’t always naming a single fixed compound.
Vial Sizing and Mass Labeling
Tesamorelin is most commonly listed in vials ranging from 2 mg to 10 mg of lyophilized peptide. CJC-1295 listings tend to cluster around smaller nominal masses, often 2 mg or 5 mg per vial, though this varies by seller. Neither convention is fixed by any standard, so vial mass has to be read directly off each listing rather than assumed from category. Some sellers list both compounds using the same vial format and packaging, which can make the two look interchangeable in size when the underlying nominal mass per vial actually differs.
Documentation and Certificate of Analysis Differences
Both compounds warrant a Certificate of Analysis (COA) confirming identity and purity, but listings differ in how much of that documentation is surfaced. Tesamorelin listings, because the molecule is a single defined structure, more often show a COA referencing a single named peptide. CJC-1295 listings sometimes show a COA that doesn’t specify DAC status explicitly in the tested-compound name, which forces a reader to cross-reference the molecular weight on the COA against the expected weight for the DAC or non-DAC form to confirm which one was actually tested. That cross-check is one of the more reliable ways to catch an underspecified CJC-1295 listing.
Price-per-mg Presentation
Nominal price alone doesn’t tell you which listing is better value, because vial mass differs between the two compounds and even between sellers of the same compound. The relevant figure is price divided by vial mass in mg.
Take a tesamorelin listing showing a 10 mg vial priced at $150, and a CJC-1295 listing showing a 5 mg vial priced at $80.
Tesamorelin: $150 ÷ 10 mg = $15 per mg CJC-1295: $80 ÷ 5 mg = $16 per mg
Despite the CJC-1295 vial carrying a lower sticker price, its price per mg is slightly higher once vial mass is accounted for. This is a case-specific example, not a general rule about which compound runs cheaper — the only way to know is to compute price per mg from the actual numbers on each listing being compared.
A Side-by-Side Comparison
| Listing Element | Tesamorelin | CJC-1295 |
|---|---|---|
| Structural variants | Single fixed structure | DAC and non-DAC forms exist |
| Naming ambiguity risk | Low | Higher if DAC status is unstated |
| Typical vial mass range | 2–10 mg | 2–5 mg (varies by seller) |
| COA molecular weight check useful | Occasionally | Yes, to confirm DAC vs non-DAC |
| Price comparison basis | Price per mg | Price per mg |
Reading Stacked or Bundled Listings
Some sellers list tesamorelin and CJC-1295 together as a bundled item, sometimes alongside other GHRH or GHRP-category peptides. A bundled listing should still state the mass and, where relevant, the DAC status of each component separately — a combined price without a per-compound mass breakdown makes it impossible to calculate price per mg for either peptide individually. A side-by-side reference such as the CJC-1295/Ipamorelin vs. tesamorelin comparison from HEEZ Research lays out how these compounds are typically documented when placed next to each other, which is useful context when a bundled listing collapses that detail into a single line item.
What to Check Before Comparing Two Offers
Before treating two listings as comparable, confirm four things: whether the CJC-1295 listing specifies DAC status, whether both listings state vial mass in the same unit, whether a COA is available and matches the named compound’s expected molecular weight, and whether price is presented per vial or already normalized to price per mg. Skipping any of these checks risks comparing two listings that aren’t actually describing equivalent quantities. Buyers cross-referencing tesamorelin offers across multiple sellers, including through a peer tesamorelin listing catalog, will typically run this same set of checks before treating a price comparison as meaningful.
Summary
Tesamorelin vs CJC-1295 listing differences come down to a few recurring points: CJC-1295 carries a naming ambiguity tesamorelin doesn’t, vial mass conventions differ between the two, COA documentation sometimes needs a molecular-weight cross-check on CJC-1295 specifically, and any price comparison only means something once it’s normalized to price per mg. Reading past the shared “GHRH analog” framing to these listing-level specifics is what makes a comparison between the two compounds actually useful.